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Abstract
Medulloblastomas are the most common malignant brain tumors in children1. Identifying and 
understanding the genetic events that drive these tumors is critical for the development of more 
effective diagnostic, prognostic and therapeutic strategies. Recently, our group and others 
described distinct molecular subtypes of medulloblastoma based on transcriptional and copy 
number profiles2–5. Here, we utilized whole exome hybrid capture and deep sequencing to identify 
somatic mutations across the coding regions of 92 primary medulloblastoma/normal pairs. 
Overall, medulloblastomas exhibit low mutation rates consistent with other pediatric tumors, with 
a median of 0.35 non-silent mutations per megabase. We identified twelve genes mutated at 
statistically significant frequencies, including previously known mutated genes in 
medulloblastoma such as CTNNB1, PTCH1, MLL2, SMARCA4 and TP53. Recurrent somatic 
mutations were identified in an RNA helicase gene, DDX3X, often concurrent with CTNNB1 
mutations, and in the nuclear co-repressor (N-CoR) complex genes GPS2, BCOR, and LDB1, 
novel findings in medulloblastoma. We show that mutant DDX3X potentiates transactivation of a 
TCF promoter and enhances cell viability in combination with mutant but not wild type beta-
catenin. Together, our study reveals the alteration of Wnt, Hedgehog, histone methyltransferase 
and now N-CoR pathways across medulloblastomas and within specific subtypes of this disease, 
and nominates the RNA helicase DDX3X as a component of pathogenic beta-catenin signaling in 
medulloblastoma.
Medulloblastomas are aggressive tumors of primitive neuroectodermal origin. More than 
one third of patients diagnosed with medulloblastoma succumb to their disease within 5 
years6 and surviving patients often have significant long-term adverse effects from current 
therapies. Identifying the underlying genetic events responsible for medulloblastomas can 
help guide the development of more effective therapies and refine the selection of currently 
available chemotherapy and radiotherapy. Recent efforts profiling transcriptional and DNA 
copy number changes in medulloblastoma have provided insights into the biological 
processes involved in these tumors and have underscored the molecular heterogeneity of this 
disease2–4. Based on these data, four broad subgroups have been established, known 
according to a consensus nomenclature as SHH, WNT, Group 3 and Group 45.
Recently, Parsons et al. reported the first genome-scale sequencing of protein coding regions 
in medulloblastoma7. They identified alteration of genes encoding for histone modification 
proteins in 20% of cases, most notably MLL2 and MLL37. This initial survey was limited by 
a small discovery sample size (22 patients), lack of subtype-specific analysis, and use of 
Sanger sequencing technology insensitive to variants present at low allelic fraction. Here we 
survey coding somatic mutations at deeper coverage in a larger cohort of 92 
medulloblastoma/normal pairs and assess these mutations in the context of specific 
molecular subtypes (Supplemental Table 1).
In total, 1,908 mutations were detected within 1,671 of 18,863 genes sequenced to a median 
of 106X coverage (Supplemental Table 2). Confirmation of 20 candidate mutations in 
selected genes (CTNNB1, DDX3X, SMARCA4, TP53, and CTDNEP1) was performed by 
amplification of 48 exons using a microfluidic PCR device (Fluidigm) followed by single-
molecule real-time sequencing (SMRT, Pacific Biosciences) (Supplemental text). Sequence 
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data was unavailable for one DDX3X mutation due to poor PCR amplification from the 
sample. All remaining 19 mutations were confirmed by this orthogonal method (median 73 
redundant subreads, range 3–287, Supplemental Figure 1).
A median of 16 somatic mutations (12 non-silent, 4 silent) per tumor was identified, 
corresponding to a mutation rate of 0.35 non-silent mutations per megabase of callable 
sequence, less than most adult solid tumors and consistent with results from Parsons et al7. 
Six of the twelve most frequently mutated tumors were from the oldest patients (16–31 years 
at diagnosis), consistent with increased mutation frequency in adult versus childhood 
medulloblastomas (p=7.7×10−5, Wilcoxon rank-sum test, Supplemental Figure 2).
To identify genes mutated at statistically significant frequencies across our cohort, we 
utilized the MutSig algorithm8 which takes into account gene size, sample-specific mutation 
rate, non-silent to silent mutation ratios, clustering within genes, and base conservation 
across species. In our cohort of 92 samples, we identified 12 significantly mutated genes (q 
< 0.1, Table 1, Supplemental Table 3). Strikingly, these genes were not mutated in c5 
(Group 3) and c4 (Group 4) tumors with extensive somatic copy number alteration (Figure 
1), suggesting these subtypes are driven primarily by structural variation, rather than base 
mutation. Not unexpectedly, CTNNB1 (beta-catenin) and PTCH1 were the two most 
significantly mutated genes (see Table 1, Figure 1). Point mutations of CTNNB1 in 
combination with loss of chromosome 6 were found in all WNT subgroup tumors and were 
concurrent with several other recurrently mutated genes, namely CSNK2B, DDX3X, TP53 
and SMARCA4. Mutations involving PTCH1 occurred exclusively in SHH subgroup tumors 
and mutations of genes associated with the Hedgehog (Hh) pathway were also restricted to 
this subgroup (p < 0.0001, Fisher’s exact test). All but one of the tumors with PTCH1 
mutations had somatic loss of 9q, resulting in hemizygosity for the mutant allele. The 
remaining tumor had apparent copy neutral loss-of-heterozygosity of 9q22. Other somatic 
mutations of Hh pathway members include a splice site mutation in SUFU, an in-frame 
deletion in WNT6, and missense mutations in GLI2, SMO, PRKACA, WNT2, and WNT2B.
Two patients with SHH subgroup tumors had germline variants in PTCH1, one with somatic 
loss of 9q resulting in hemizygosity for a loss-of-function germline allele (MD-085, c.
3030delC, p.Asn1011Thrfs*38) and the other with a substitution previously reported in 
patients with holoprosencephaly (MD-286, p.T1052M9). Two additional cases (MD-097 and 
MD-335) had loss-of-function variants in SUFU (1 frameshift deletion and 1 nonsense) that 
began as heterozygotes in the germline and became hemizygous in the tumor, due to somatic 
loss of chromosome 10 in one case and copy neutral loss-of-heterozygosity in the other.
MLL2 was also subject to recurrent inactivating mutations, consistent with findings by 
Parsons et al7 and providing further evidence for dysregulated histone modification in 
medulloblastoma. Indeed, six of the twelve most significantly mutated genes are involved in 
histone modification and/or related chromatin remodeling complexes (MLL2, GPS2, 
KDM6A, BCOR, SMARCA4, and LDB1; see Table 1). As a gene set, histone 
methyltransferases (HMTs) were enriched for somatic mutation with 21 tumors having 
apparent, predominantly loss-of-function, HMT mutations (q = 5.8×10−9; Figure 2, 
Supplemental Table 4).
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Subtype-specific MutSig analysis identified additional significant mutations of histone 
modifying genes, MLL3 and HDAC2, in Group 4 tumors along with KDM6A mutations 
(q=0.039 and 0.066, see Supplemental Table 3). Mutations in KDM6A, interestingly, 
occurred exclusively in tumors with an i17q as the sole autosomal alteration (p = 0.0023, 
Fisher’s exact test) with the one female case with KDM6A mutation also having loss of a 
chromosome X. Notably, the two ‘i17q only’ tumors without KDM6A mutations had other 
histone modifying enzymes mutated, namely THUMPD3, ZMYM3 and MLL3, perhaps 
suggesting a distinct biology for tumors with this karyotype.
Mutations in several genes encoding components of the nuclear co-repressor (N-CoR) 
complex were observed at a statistically significant frequency: BCOR in 3 tumors, GPS2 in 
3 tumors, and LDB1 in 2 tumors. BCOR mutations have recently been reported at high 
frequency in retinoblastoma10 and in ‘copy-neutral’ acute myelogenous leukemia11. BCOR 
is located on the X-chromosome and two hemizygous frameshift mutants were found in 
tumors from males (allele fractions 0.90 and 0.92). A third nonsense mutation was also 
found in a male but at low allelic fraction (0.12), suggesting a subclonal event. Two of three 
BCOR mutations occurred in SHH subgroup tumors. LDB1 missense and nonsense 
mutations were found in two additional SHH tumors, both appearing hemizygous due to loss 
of 10q and complete chromosome 10 loss, respectively (allele fractions 0.81 and 0.78). Both 
BCOR and LDB1 promote assembly of the repressive N-CoR complex12 and harbor 
apparent loss of function mutations. GPS2, which encodes a critical subunit of the N-CoR 
complex, a repressor of JNK/MAPK signaling through partnership with histone 
deacetylases12, was mutated in two Group 3 tumors. The GPS2 mutations cluster within 
amino acids 53 – 90, the domain critical for heterodimerization with NCOR2 (SMRT) and 
interacting with a TBL1-NTD tetramer to assemble the N-CoR repression complex12. 
Finally, an additional nonsense mutation in NCOR2 was identified in a single SHH subgroup 
tumor, underscoring the central role of N-CoR dysregulation in medulloblastoma 
development and particularly within the SHH subgroup.
Several genes encoding subunits of the SWI/SNF-like chromatin-remodeling complex were 
also mutated in our cohort, including significant recurrent mutations of SMARCA4 (Brg/
BAF190), which encodes a DNA helicase with ATPase activity13 and has been reported to 
be mutated in lung, ovarian, and pancreatic cancers14 as well as medulloblastoma15. In our 
cohort, SMARCA4 (Brg/BAF190) mutations clustered in helicase domains and occurred in 
three Group 3 tumors (significant within the c1 subtype, q=0.019), and one WNT tumor. In 
addition, mutations were found in the alternative ATPase subunit SMARCD2 (Brm) 
(missense at a highly conserved residue) and two other members of the SWI/SNF complex, 
ARID1B (BAF250b) (2 bp frameshift deletion) and SMARCC2 (BAF170) (splice site). These 
were all apparent loss-of-function mutations and occurred in SHH tumors. Thus, it appears 
that disruption of this complex is frequent across medulloblastomas.
Novel and hemizygous mutations were found in CTDNEP1 (previously known as 
DULLARD), a phosphatase with roles in Xenopus neural development through regulation of 
BMP receptors16, and as a direct regulator of LIPIN, an integral component of the mTOR 
complex17. CTDNEP1 mutations were found in two Group 3 tumors (significant within the 
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subtype, q=0.0087), a 2 bp frameshift deletion and a substitution disruptive of a splice site. 
Both tumors have i17q chromosomes resulting in loss of the wild type allele at 17p13.
Mutations in DDX3X, an ATP-dependent RNA helicase with functions in transcription, 
splicing, RNA transport and translation18, were found in seven tumors, including half of the 
WNT pathway tumors (p = 0.005, Fisher’s exact test) and several SHH subgroup tumors. 
DDX3X mutations have recently been reported at low frequency in five other tumor types 
(Catalogue of Somatic Mutations in Cancer, COSMIC15) but the significance of these 
mutations for DDX3X function remains unclear. To understand the consequence of 
observed point mutations on DDX3X’s physical structure, we mapped the mutations onto 
the previously reported crystal structure of DDX3X19 and its ortholog Vasa/DDX420 (Figure 
3a; Supplemental Figure 3; Supplemental table 5). The mutations appear to cluster in two 
structural domains, a helicase ATP-binding domain (residues 211–403) and a helicase C-
terminal domain (residues 414–575). The location of these mutations suggests that they may 
alter DDX3X-RNA interaction (Figure 3a; Supplementary table 5).
As half of the beta-catenin mutated tumors contained concurrent DDX3X mutations, we 
investigated whether DDX3X could enhance beta-catenin’s ability to transactivate a TCF4-
luciferase reporter (TOPflash) and if DDX3X/beta-catenin co-expression had a measureable 
effect on cell viability/proliferation. In combination with wild-type beta-catenin, neither 
wild type nor mutant DDX3X alone significantly transactivated the TOPflash reporter. 
However, in combination with mutant beta-catenin (S33Y substitution), the majority of 
DDX3X point mutants in our cohort potentiated reporter activity (Figure 3b; p < 0.05). This 
potentiation was also apparent in cell viability assays in both HeLa (data not shown) and 
D425 medulloblastoma cell lines (Figure 3c; p < 0.05).
Given the apparent importance of DDX3X mutations in medulloblastoma, we searched the 
genes listed in the RNA Helicase Database30 for low frequency mutations in 
medulloblastoma. We found five tumors with mutations within RNA helicase or RNA 
binding domains of DHX9, DHX32, DHX57, FANCM and SKIV2L (Figure 2, Supplemental 
Table 6). The missense mutations were at conserved residues and predicted to be deleterious 
by SIFT, AlignGVGD, and PolyPhen2. In addition, a frameshift insertion in SETX occurs 
upstream of, and likely disrupts, its RNA helicase domain. Overall, 15% of 
medulloblastomas appear to have some disruption of RNA helicase activity.
In summary, we report a next-generation sequencing analysis of medulloblastoma, the most 
common malignant brain tumor in children. Our results reveal mutations in several known 
pathways such as histone methylation (MLL2 and others), sonic hedgehog (PTCH1, SUFU, 
and others) and Wnt (CTNNB1 and others), and also mutations in novel genes including 
DDX3X, BCOR, LDB1, and GPS2. Our preliminary functional studies implicate DDX3X as 
a candidate component of pathogenic WNT/beta-catenin signaling. In a broader sense, 
DDX3X mutations have recently been reported in chronic lymphocytic leukemia21 and head 
and neck cancers22, both of which have subsets of tumors with dysregulated WNT signaling. 
Studies investigating whether mutant DDX3X functions complicit with beta-catenin in these 
contexts should provide additional insights into this multifaceted molecule and open 
potential avenues for novel therapies. Finally, the delineation of nuclear receptor co-
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repressor complex molecules as altered in medulloblastoma provides new insight into the 
pathogenesis of this deadly childhood disease.
Methods Summary
Informed consent was provided by families of medulloblastoma patients treated at 
Children’s Hospital Boston, The Hospital for Sick Children Toronto and institutions 
contributing to the Children’s Oncology Group/Cooperative Human Tissue Network, under 
approval and oversight by their respective Internal Review Boards. All tumors were 
obtained at the initial surgical resection and recurrent tumors were excluded from our 
analysis. Hematoxylin and eosin stained slides of tumor samples were pathologist reviewed 
to confirm the diagnosis of medulloblastoma, determine histological subtype when able, and 
assess tumor purity. DNA was isolated from tumor specimens and matched peripheral blood 
as previously described2. Exome sequencing of DNA from 92 tumor/normal pairs was 
performed using in-solution hybrid-capture of 193,094 exons from 18,863 miRNA- and 
protein-coding genes, followed by sequencing of 76 bp paired-end reads using Illumina 
sequencing-by-synthesis technology23. Reads were aligned to human genome build 
GRCh3724 using Burrows-Wheeler aligner25. The ~33 Mb target region was sequenced to 
106X mean coverage in each sample (range 73 – 234). Gene expression data and copy 
number profiles (derived from SNP microarrays or sequence data) were used to assign each 
tumor to a subgroup using published criteria2. Our cohort consisted of 6 WNT(c6), 23 
SHH(c3), 33 Group 3(12 c1, 21 c5), and 30 Group 4(12 c2, 18 c4) tumors (see Supplemental 
Table 1 for case annotations). Mutations were detected using muTect, annotated using 
Oncotator26, and manually reviewed using the Integrated Genomics Viewer (IGV)27. For 
validation, PCR on Access Array microfluidic chips (Fluidigm) was followed by single-
molecule real-time sequencing (Pacific Biosciences) per manufacturer’s instructions. 
Subreads were extracted and assigned to samples using manufacturer’s and custom software, 
and aligned to the hg19 (GRCh37) build of the human reference genome sequence using 
BWA-SW25. Candidate mutations were confirmed by manual review using IGV27 
(Supplemental Figure 1). See Supplementary Information and http://www.broadinstitute.org/
cancer/cga/ for complete descriptions of materials and methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was supported by NIH grants NHGRI U54HG003067 to ES Lander (ES, DA, SBG, GG, MM); 
R01CA109467(SLP, JPM); R01CA105607(HG, TMR, MM, SLP); P30 HD18655(SLP); R01 CA030002 and 
CA050661 (TMR); R01 NS046789(GRC); R01 CA154480(PT); R25NS070682(SS) and R01CA148699(MDT); St. 
Baldrick’s Foundation Scholar Award and the Beirne Faculty Scholar endowment and Center for Children’s Brain 
Tumors at Stanford University (YJC); German Cancer Aid (109252) and the BMBF ICGC-PedBrain project (NJ, 
DTWJ, PL, SMP); HHMI (GRC); the Pediatric Brain Tumor Foundation(MDT); Canadian Institutes of Health 
Research Fellowship (TJP); Restracomp funding from the Hospital for Sick Children (PAN); and the Mullarkey 
Research Fund (SLP). We thank Children’s Oncology Group and the Cooperative Human Tissue Network for 
providing tumor samples, the staff of the Broad Institute Biological Samples, Genome Sequencing and Genetic 
Analysis Platforms for their assistance in genomic processing of samples and generating the sequencing data used 
in this analysis, K. Keho and M. Brown at Pacific Biosciences for technical support with sample barcoding 
methods, and L. Gaffney of Broad Institute Communications for assistance with figure layout and design.
Pugh et al. Page 6
Nature. Author manuscript; available in PMC 2013 February 02.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
References
1. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the 
United States in 2004–2007. Central Brain Tumor Registry of the United States; Hinsdale, IL: 2011. 
at <www.cbtrus.org>
2. Cho YJ, et al. Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup 
That Drives Poor Clinical Outcome. Journal of Clinical Oncology. 2011; 29:1424–1430. [PubMed: 
21098324] 
3. Kool M, et al. Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic 
Profiles, Pathway Signatures and Clinicopathological Features. PLoS ONE. 2008; 3:e3088. 
[PubMed: 18769486] 
4. Remke M, et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol. 
2011; 29:2717–2723. [PubMed: 21632505] 
5. Taylor MD, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta 
Neuropathologica. 201110.1007/s00401-011-0922-z
6. Smoll NR. Relative survival of childhood and adult medulloblastomas and primitive 
neuroectodermal tumors (PNETs). Cancer. 10.1002/cncr.26387
7. Parsons DW, et al. The Genetic Landscape of the Childhood Cancer Medulloblastoma. Science. 
2010; 331:435–439. [PubMed: 21163964] 
8. Getz G, et al. Comment on “The Consensus Coding Sequences of Human Breast and Colorectal 
Cancers. Science. 2007; 317:1500. [PubMed: 17872428] 
9. Ming J, et al. Mutations in PATCHED-1, the receptor for SONIC HEDGEHOG, are associated with 
holoprosencephaly. Human Genetics. 2002; 110:297–301. [PubMed: 11941477] 
10. Zhang J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 
2012; 481:329–334. [PubMed: 22237022] 
11. Grossmann V, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute 
myeloid leukemia with normal karyotype. Blood. 2011; 118:6153–6163. [PubMed: 22012066] 
12. Oberoi J, et al. Structural basis for the assembly of the SMRT/NCoR core transcriptional 
repression machinery. Nat Struct Mol Biol. 2011; 18:177–184. [PubMed: 21240272] 
13. Baek SH, et al. Regulated subset of G1 growth-control genes in response to derepression by the 
Wnt pathway. Proc Natl Acad Sci U S A. 2003; 100:3245–3250. [PubMed: 12629224] 
14. Wilson BG, Roberts CWM. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011; 
11:481–492. [PubMed: 21654818] 
15. Futreal PA, et al. A census of human cancer genes. Nat Rev Cancer. 2004; 4:177–183. [PubMed: 
14993899] 
16. Satow R, Kurisaki A, Chan T-chuan, Hamazaki TS, Asashima M. Dullard Promotes Degradation 
and Dephosphorylation of BMP Receptors and Is Required for Neural Induction. Developmental 
Cell. 2006; 11:763–774. [PubMed: 17141153] 
17. Peterson TR, et al. mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP 
Pathway. Cell. 2011; 146:408–420. [PubMed: 21816276] 
18. Garbelli A, Beermann S, Di Cicco G, Dietrich U, Maga G. A Motif Unique to the Human Dead-
Box Protein DDX3 Is Important for Nucleic Acid Binding, ATP Hydrolysis, RNA/DNA 
Unwinding and HIV-1 Replication. PLoS ONE. 2011; 6:e19810. [PubMed: 21589879] 
19. Högbom M, et al. Crystal structure of conserved domains 1 and 2 of the human DEAD-box 
helicase DDX3X in complex with the mononucleotide AMP. J Mol Biol. 2007; 372:150–159. 
[PubMed: 17631897] 
20. Sengoku T, Nureki O, Nakamura A, Kobayashi S, Yokoyama S. Structural basis for RNA 
unwinding by the DEAD-box protein Drosophila Vasa. Cell. 2006; 125:287–300. [PubMed: 
16630817] 
21. Wang L, et al. SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia. New 
England Journal of Medicine. 2011; 365:2497–2506. [PubMed: 22150006] 
22. Stransky N, et al. The Mutational Landscape of Head and Neck Squamous Cell Carcinoma. 
Science. 2011; 333:1157–1160. [PubMed: 21798893] 
Pugh et al. Page 7
Nature. Author manuscript; available in PMC 2013 February 02.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
23. Bentley DR, et al. Accurate whole human genome sequencing using reversible terminator 
chemistry. Nature. 2008; 456:53–59. [PubMed: 18987734] 
24. Genome Reference Consortium. at <http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/
projects/genome/assembly/grc/index.shtml>
25. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. 
Bioinformatics. 2009; 25:1754–1760. [PubMed: 19451168] 
26. Ramos, Alex, et al. Oncotator. at <http://www.broadinstitute.org/oncotator/>
27. Robinson JT, et al. Integrative genomics viewer. Nat Biotech. 2011; 29:24–26.
28. Ren J, et al. DOG 1.0: illustrator of protein domain structures. Cell Res. 2009; 19:271–273. 
[PubMed: 19153597] 
29. Pettersen EF, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J 
Comput Chem. 2004; 25:1605–1612. [PubMed: 15264254] 
30. Jankowsky, Anja; Guenther, Ulf-Peter; Jankowsky, Eckhard. The RNA helicase database. Nucl 
Acids Res. 2011; 39(suppl 1):D338–D341. first published online November 25, 2010. 
10.1093/nar/gkq1002 [PubMed: 21112871] 
Pugh et al. Page 8
Nature. Author manuscript; available in PMC 2013 February 02.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. Demographic characteristics, molecular subtypes and selected copy number alterations 
and somatic mutations across 92 medulloblastoma cases
Data tracks describing 92 medulloblastoma cases. Identifier: Unique name used to denote 
each case. Identifiers also link samples to those analyzed by Cho et al. Sex: males in blue, 
females in pink. Age: years of age at diagnosis binned as infants, children, or adults. 
Histology: pathology review of primary tissue specimen. Subtypes: based on copy number 
profiles derived from sequence or microarray data. Consensus subtypes from Taylor et al. 
Cho et al subtypes as published. Copy number alterations: Selected copy number 
alterations used to assign tumors to subtypes. Losses are blue. Gains are red. Somatic 
mutations: Gene names (HUGO symbols) grouped by functional category. MutSig gene 
names are in bold. Missense mutations are black, nonsense/splice site/indel mutations are 
orange, silent mutations are purple, and germline variants are green.
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Figure 2. Location of mutations in histone methyltransferases, RNA helicases, and N-CoR 
complex-associated genes
Location of somatic mutations on linear protein domain models of genes from sets 
frequently mutated in medulloblastoma. All domain annotations are from UniProt and 
InterPro annotations. Diagrams were constructed using Domain Graph (DOG)28, version 
2.0. a. Histone methyltransferase domains: red = SET, green = coiled-coil, blue = zinc-
finger, and cyan=other. b. N-CoR complex-associated domains: purple = anti-parallel 
coiled-coil domains required for GPS2/NCOR2 (SMRT) interaction12, yellow = other 
interaction domains as labeled: SANT domains binds DNA; CoRNR domains binds nuclear 
receptors; ANK repeats mediate a diversity of protein-protein interactions, and LIM-binding 
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domains bind a common protein structural motif. c. RNA helicase domains: cyan = helicase 
and helicase-associated (InterPro), red = RNA-binding and RNA polymerase sigma factor 
(InterPro), blue = ATP binding site, and green = DEAD or DExH box motif. See 
Supplemental Table 1 for UniProt protein model identifiers.
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Figure 3. Functional consequence of DDX3X point mutations
a, Three-dimensional model of the two recA-like domains of human DDX3X in complex 
with single-stranded RNA and a Mg-ATP analog. Displayed are the residues mutated in the 
N-terminal recA-like domain (R276K, D354H, R376C) and C-terminal recA-like domain 
(D506Y, R528H, R534H, P568L). Coloring: DDX3X residues 166–405 (light blue); 
DDX3X residues 406–582 (dark blue); single-stranded RNA (cyan); Mg-ATP analog 
(magenta and green). Molecular graphics images were produced using the University of San 
Francisco Chimera package29 (http://www.cgl.ucsf.edu/chimera). b, Mutant DDX3X 
potentiates mutant beta-catenin transactivation of TOPflash promoter. Represented is 
relative luciferase activity in 293T cells co-transfected with TOPflash reporter, FOPflash 
control, and either wild type or mutant DDX3Xs in combination with wild type or mutant 
beta-catenin. One-dimensional model of DDX3X displayed about bar graphs to illustrates 
the position of the mutations. c, Cell viability assays of medulloblastoma D425 cells stably 
transduced with either wild type or mutant DDX3X lentivirus in combination with either 
wild type or mutant beta-catenin lentivirus.
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For b and c, error bars depict the standard deviation of the mean from 5 replicate 
experiments performed for each condition. Student’s t-tests were performed to evaluate 
significance of differences in TOPflash intensity or cell proliferation value distributions as 
follows: increases with DDX3X alone vs. empty vector, increases with wtBetaCat vs. 
DDX3X alone, increases with mutBetaCat vs. DDX3X alone, and increases with 
mutBetaCat vs. wtBetaCat.
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